US Stock MarketDetailed Quotes
TOVX Theriva Biologics
- 2.0700
- +0.0800+4.02%
Close Nov 4 16:00 ET
- 1.8900
- -0.1800-8.70%
Post 19:31 ET
4.70MMarket Cap-66P/E (TTM)
2.0800High1.7450Low2.08MVolume1.8900Open1.9900Pre Close3.97MTurnover140.00%Turnover RatioLossP/E (Static)2.27MShares17.112552wk High0.18P/B3.08MFloat Cap1.240052wk Low--Dividend TTM1.49MShs Float52089843.7500Historical High--Div YieldTTM16.83%Amplitude1.2400Historical Low1.9050Avg Price1Lot Size
Theriva Biologics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 11.31%-3.45M | 12.99%-4.88M | 0.45%-19M | -21.85%-6.54M | 33.73%-2.95M | 10.65%-3.89M | -14.44%-5.61M | -48.04%-19.08M | -11.60%-5.37M | -106.68%-4.46M |
| Net income from continuing operations | -63.54%-8.32M | -15.34%-5.17M | 6.79%-18.35M | 14.90%-5.49M | 26.48%-3.3M | -13.58%-5.09M | -4.80%-4.48M | -37.97%-19.69M | -22.46%-6.45M | -37.18%-4.49M |
| Depreciation and amortization | 18.75%38K | 21.88%39K | 58.82%135K | 56.00%39K | 33.33%32K | 77.78%32K | 77.78%32K | -2.30%85K | 92.31%25K | 33.33%24K |
| Deferred tax | 38.44%-221K | 32.42%-223K | -15.09%-1.64M | 24.01%-424K | -57.31%-527K | 32.52%-359K | ---330K | ---1.43M | ---558K | ---335K |
| Other non cash items | -134.59%-184K | 42.86%310K | -188.08%-2M | -154.05%-1.29M | -697.96%-1.47M | 234.01%532K | 382.22%217K | 1,269.88%2.27M | --2.38M | --245K |
| Change In working capital | 17.70%991K | 99.83%-2K | 386.48%2.31M | 152.33%471K | 10,447.62%2.17M | -8.38%842K | -46.39%-1.18M | -213.68%-806K | -652.15%-900K | -102.11%-21K |
| -Change in prepaid assets | -49.60%252K | 271.36%766K | 461.98%1.31M | 86.35%-156K | 440.84%1.42M | 290.63%500K | -214.62%-447K | -308.62%-363K | -929.73%-1.14M | 423.46%262K |
| -Change in payables and accrued expense | 91.95%858K | -3.65%-653K | 544.20%1.42M | 207.08%737K | 435.80%863K | -46.98%447K | 44.98%-630K | -142.48%-319K | -46.07%240K | -123.73%-257K |
| -Change in other current liabilities | -13.33%-119K | -15.00%-115K | -240.32%-422K | -3,766.67%-110K | -311.54%-107K | -101.92%-105K | -104.08%-100K | 42.59%-124K | 106.25%3K | 44.68%-26K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 11.31%-3.45M | 12.99%-4.88M | 0.45%-19M | -21.85%-6.54M | 33.73%-2.95M | 10.65%-3.89M | -14.44%-5.61M | -48.04%-19.08M | -11.60%-5.37M | -106.68%-4.46M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 88.89%-1K | 0 | 95.40%-202K | 38.46%-56K | -1,072.73%-129K | 35.71%-9K | 99.81%-8K | -31,300.00%-4.4M | -91K | -11K |
| Net PPE purchase and sale | 88.89%-1K | --0 | -74.14%-202K | 38.46%-56K | -1,072.73%-129K | 35.71%-9K | ---8K | -728.57%-116K | ---91K | ---11K |
| Net business purchase and sale | ---- | ---- | --0 | --0 | ---- | ---- | ---- | ---4.28M | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 88.89%-1K | --0 | 95.40%-202K | 38.46%-56K | -1,072.73%-129K | 35.71%-9K | 99.81%-8K | -31,300.00%-4.4M | ---91K | ---11K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -16.99%1.77M | 0 | 132.38%625K | 55.69%-1.46M | -99.96%1K | 2.14M | 96.00%-55K | -102.61%-1.93M | -3.29M | 2.73M |
| Net issuance payments of debt | -235.00%-67K | --0 | 94.55%-75K | --0 | --0 | ---20K | 96.00%-55K | ---1.38M | --0 | --0 |
| Net common stock issuance | ---- | ---- | 870.49%2.22M | 121.53%62K | --1K | ---- | ---- | -100.44%-288K | ---288K | --0 |
| Net preferred stock issuance | ---- | ---- | --0 | --0 | ---- | ---- | ---- | --2.73M | --0 | ---- |
| Net other financing activities | ---- | ---- | 49.37%-1.52M | ---- | ---- | ---- | ---- | ---3M | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -16.99%1.77M | --0 | 132.38%625K | 55.69%-1.46M | -99.96%1K | --2.14M | 96.00%-55K | -102.61%-1.93M | ---3.29M | --2.73M |
| Net cash flow | ||||||||||
| Beginning cash position | -49.25%18.36M | -44.42%23.28M | -37.79%41.89M | -38.20%31.26M | -34.40%34.35M | -36.30%36.18M | -37.79%41.88M | 981.18%67.33M | -29.88%50.58M | -29.52%52.36M |
| Current changes in cash | 4.82%-1.68M | 13.96%-4.88M | 26.90%-18.57M | 7.92%-8.05M | -77.78%-3.08M | 59.61%-1.77M | 46.27%-5.67M | -141.59%-25.41M | -81.85%-8.75M | 19.62%-1.73M |
| Effect of exchange rate changes | 119.05%12K | -8.57%-38K | -3.13%-33K | 46.15%76K | 77.55%-11K | 0.00%-63K | -225.00%-35K | ---32K | --52K | ---49K |
| End cash Position | -51.40%16.69M | -49.25%18.36M | -44.42%23.28M | -44.42%23.28M | -38.20%31.26M | -34.40%34.35M | -36.30%36.18M | -37.79%41.89M | -37.79%41.89M | -29.88%50.58M |
| Free cash flow | 11.48%-3.45M | 13.12%-4.88M | 0.00%-19.2M | -20.85%-6.6M | 31.01%-3.08M | 10.73%-3.9M | -14.61%-5.62M | -48.78%-19.2M | -13.49%-5.46M | -107.19%-4.47M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
